IMBRUVICA, generically known as ibrutinib, is a targeted therapy medication used in the treatment of several types of blood cancers, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinemia, among others. It belongs to a class of drugs known as Bruton's tyrosine kinase (BTK) inhibitors, which work by blocking BTK, a key protein that cancer cells need to multiply and spread. By inhibiting this protein, IMBRUVICA can help to slow or stop the growth of cancer cells. It is administered orally in capsule or tablet form, making it a convenient option for patients. Since its approval, IMBRUVICA has become a significant advancement in the treatment of these complex blood cancers, offering hope to patients with its targeted approach and the potential for improved outcomes.
When using IMBRUVICA, it is crucial to adhere strictly to your doctor's instructions and thoroughly read the label that accompanies the medication. This ensures you are aware of the correct dosage and any specific precautions you need to take. Common side effects of IMBRUVICA include diarrhea, fatigue, muscle and bone pain, rash, fever, and bruising. Less common, but more severe side effects can include bleeding problems, infections, heart rhythm abnormalities, and high blood pressure. Due to the risk of bleeding, be cautious when using sharp objects or engaging in activities that could result in cuts or injuries. It's also important to inform your healthcare provider about all other medications you are taking, as IMBRUVICA can interact with other drugs, potentially leading to adverse effects. Given the potential for side effects like fatigue and dizziness, caution is advised when driving or operating heavy machinery until you know how IMBRUVICA affects you. Always consult your healthcare provider if you experience any unusual symptoms or if you have concerns about the medication's effects.